If they plan on spending the money it really is pointless to try to value this company based on cash. It's all about potential future revenue and how long it will take to get there.
Sorry, but nobody pays $2 billion for a company trading at $400 million. Maybe double @ $800 million at best. Need the PPS to go up for a better price.
Exactly. Eve said in a presentation about the Dr. Glass Immuno-suppression trial and she said the answer to "were that was responsible for the patients improvement" and she said the answer was "no".
That is correct Dr Glass at Emory did a trial with the same protocol minus the cells. Some time ago she said they did this trial to see if it was the immune suppression and she said the answer was "no".
Thanks. Hopefully some great news for the patients. Financial gain is so irrelevant when you consider those affected by ALS.
If Imetelstat works as well in J&J trials as it did in Mayo's trial it will consume INCY's market cap as money move out of INCY and into Geron.... And then some
anne, Scarlet said that there were plans for as many as 80 sites. He didn't state that they already had eighty sites.
Picking patients based on mutations is not cherry picking. Your trying to get the therapy to people it will help the most. Cherry picking is when investigators intentionally or unintentionally get patients which have the best survival chances to enroll in a trial. It's pretty hard to cherry pick when you have 80 sites across the world.
Hopefully during this time the MDS trial starts and hopefully we will have some vocal MF patients like irishtrader. We could also get updates on plans for trials for other indications.
I have little doubt that Imetelstat will make it to market but the FDA hold (perhaps unfair) created doubt about safety that still lingers. Also the Mayo MF study was 1 site with Dr. T in control. Some would be concerned that patients could be cherry picked. I'm pretty darn sure they weren't but analyst do consider these things.
In 4 or 5 months we will have results from multiple sites and investigators from around the world. The proof of efficacy and a path to approval will become certain.
I agree that JNJ is not in a hurry to buy GERN out but I do believe it could happen if the top line Phase 2 data is extremely positive (similar to Mayo results)
Given that the transfer of Imetelstat development is already likely transferred to Janssen it is highly unlikely that anyone other than Janssen will buy them out.
Certainly no one other than JnJ/Janssen would attempt a buyout of Geron at this point. Given that all Imetelstat development has been transfered to Janssen it would be too messy to untransfer it and would cause clinical delays.
Not sure where you are gettting the 20-30% number from. It's much more dramatic than that. In the case of the one genetic mutation 38% of patients with the mutation had a CR/PR versus 4% of patients who did not have the mutation. That means that it was 950% (38 divided by 4) more effective on patients with that mutation.
Also if compare it to INCY's Jak inhibitor which has 0% CR/PRs it would be infinite% (38/0) more effective.
The Janssen agreement if for all oncology applications of Imetelstat world wide